Hi mattyedw what I am seeing is that Mason Stevens Limited was fully sold down and no longer on Top20, creating headache for us holders.
There is not much to say besides the latest disappointing developments of PAB given the board is full of experience.
However we must remember in bio sector not everything will sail smoothly. For me I do still believe in deoxymab platform being unique.
Here hoping for a successful Tox study to show the middle finger to Mason Stevens limited. All IMO.
Ann: Appendix 4C - Quarterly - 31 March 2023, page-102
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $43.28K | 6.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237374 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1732079 | 8 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| PAB (ASX) Chart |